Furthermore, SIRT1 activation by cystatin C could shift APP processing toward a non-amyloidogenic pathway in BMECs, providing a potential target for the treatment of Alzheimer’s disease [79]. This evidence concerns the gene SIRT1 and early-onset autosomal dominant Alzheimer disease.